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Abstract: Chronic proliferation is a major hallmark of tumor cells. Rapidly proliferating cancer cells
are highly dependent on nutrients in order to duplicate their cell mass during each cell division.
In particular, essential amino acids are indispensable for proliferating cancer cells. Their uptake
across the cell membrane is tightly controlled by membrane transporters. Among those, the L-type
amino acid transporter LAT1 (SLC7A5) has been repeatedly found overexpressed in a vast variety of
cancers. In this review, we summarize the most recent advances in our understanding of the role of
LAT1 in cancer and highlight preclinical studies and drug developments underlying the potential of
LAT1 as therapeutic target.
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1. Introduction: LAT1 Transporter
Sustained proliferative signaling is a major hallmark of cancer [1]. These signals initiate tumor
cells division, resulting in rapid growth in an uncontrolled way. The duplication of cell mass is highly
demanding of energy and depends on the availability of nutrients in the tumor microenvironment.
Among these nutrients, glucose is the most famous leading to the use of glucose uptake imaging to
evidence tumors and metastases. Apart from glucose, essential amino acids (EAA) were described to
be indispensable for cell proliferation in vitro by Harry Eagle in 1955, since HeLa cells rapidly died
when a single EAA was omitted from the medium [2]. Subsequently, EAA uptake was demonstrated
to be higher in tumors in vivo compared to normal tissues [3–5], suggesting that increased EAA
uptake is required to maintain protein synthesis in highly proliferative cancers [6]. EAA uptake
across the plasma membrane is tightly controlled by amino acid transporters or Solute Carriers (SLC).
The L-type amino acid transporter family serves as an important route for EAA entry into cells and
consists of four members (LAT1–4). In a previous extensive review, Wang and Holst reported the
literature demonstrating that among the four LAT transporters, LAT1 was predominantly found to be
overexpressed in a variety of cancers [7]. LAT1 (SLC7A5) contains 12 transmembrane domains and
covalently binds to 4F2hc (SLC3A2), which incorporates LAT1 into the plasma membrane resulting in its
functional expression [8]. LAT1 mediates the influx of neutral EAA (leucine, isoleucine, phenylalanine,
methionine, histidine, tryptophan, valine, and tyrosine) into cells [9,10] in exchange for the eﬄux of
intracellular substrates (EAA or glutamine) [11,12], thus acting as an antiporter. This review will give
an update on the role of LAT1 in cancer and its potential as a therapeutic target or drug carrier in
different malignancies.
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2. LAT1 Expression in Cancer
Studies that demonstrated an increased LAT1 expression comparing late-stage vs. early-stage
diseases or between malignant vs. normal tissues are listed in Table 1. SLC7A5/ LAT1 was found
overexpressed in a wide range of solid tumors including the most frequently diagnosed cancers such as
breast cancer [13,14], prostate cancer [15–17], and lung cancer [18–30]. Additionally, LAT1 was found
overexpressed in bladder cancer [31], bone cancer [32], brain tumors [33,34], gynecological cancers [35,
36], esophagus cancers [37–39], gastrointestinal cancers [40,41], liver [42–45], pancreas [46,47], head and
neck cancers [48], kidney cancer [49], leukemia [50], skin cancer [51–54], myeloma [55,56], sarcoma [32],
thymic carcinoma [57], and thyroid cancer [58,59]. Most of these studies detected LAT1 at the protein
level in patient-derived tissue microarrays and benign tissue was used as the control. Importantly,
LAT1 was not detected by immunohistochemical staining in most non-cancerous tissues, however,
few studies reported a positive staining in activated lymphocytes [60], uterine glands [36], as well as in
the basal layer of the esophageal and uterine mucosa [35,37,39]. In several studies LAT1 expression
was not significantly associated with tumor stage, which was described in biliary tract cancer [61],
ovarian cancer [62], lung cancer [63], and mesothelioma [64]. Therefore, since LAT1 expression does
not uniformly correlate with increased tumor stages, its functional consequence needs to be evaluated
for each cancer in preclinical models.
Table 1. Role of l-type amino acid transporter (LAT1) in different tumor types.
Cancer Type Overexpression Prognosis Downregulation Inhibition
Biliary tract [65] [60,61,65] [61] (BCH)
Bladder [31] [66] (BCH)
Bone [32]
Brain [33,34] [34]
[67,68] (BCH)
[69,70] (NP)
[71] (JPH)
Breast [13,14] [13,72] [14] [14,73] (BCH), [74,75] (NP)
Cervical [35] [76] (compound5)
Colorectal [77] [78] (KO) [78–80] (JPH), [81] (Ab)
Endometrial [36] [36] [36] [36] (BCH)
Esophageal [37–39] [38] [82] (BCH)
Gastric [40,41] [41] [83] [81] (Ab), [80] (JPH)
Head and neck [48] [48] [84] [67,85] (BCH), [86] (JPH)
Kidney [49] [49] [78] (JPH)
Leukemia [50] [50] (JPH)
Liver [42–45] [43,45,65]
Lung [18–30] [18–21,23,25,27–30,63,87] [78] (KO) [30] (BCH), [78] (JPH), [88](SKN103), [81] (Ab)
Melanoma [51–53] [51] [52,53] (BCH)
Mesothelioma [64]
Myeloma [55,56] [56]
Ovarian [62,89] [90] [91] (BCH)
Pancreatic [46,47] [46,47,92] [92] [88] (SKN103)
Prostate [15–17] [16,17] [17,93,94] [95] (JPH, BCH), [93] (BCH)
Sarcoma [32] [67] (BCH)
Skin [54]
Thymic
carcinoma [57] [96] (JPH)
Thyroid [58,59] [59] [59] (JPH)
Urinary tract [97] [97]
Overexpression: references indicate LAT1 upregulation during cancer progression (late-stage vs. early-stage or
cancer vs. normal tissue); Prognosis: references indicate shorter survival of patients with high LAT1 expression in
tumors; Downregulation: references indicate that LAT1 downregulation inhibited cancer cell growth (KO = LAT1
knockout cell line); Inhibition: references indicate that pharmacological inhibition of LAT1 by either the unspecific
LAT inhibitor BCH (2-aminobicyclo[2.2.1]heptane-2-carboxylic acid) or the LAT1 specific inhibitor JPH203 or
nanoparticles (NP) or indicated compound reduced cell growth.
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The majority of the studies are correlative and did not validate the tumorigenic role of LAT1.
However, few studies are particularly comprehensive because they provide additional functional
validation of LAT1 in cancer cell lines (breast [14], endometrial [36], leukemia [50], lung [30],
melanoma [52,53], and thyroid [59] cancer). The functional validation of LAT1 in each of these
studies (pharmacological inhibition or downregulation by RNA interference) will be discussed in this
review in Sections 3 and 4.
The mechanism(s) of LAT1 upregulation in these studies is not well understood. One hypothesis
was put forward: hypoxia could be involved since it was able to increase SLC7A5 transcription in vivo
through transcriptional activation by HIF2α [98]. Interestingly, LAT1 expression was significantly
correlated with VEGF expression in several publications [19,25,46,57] and VEGF is a well-described
hypoxia marker [99,100], which indicates that hypoxia might indeed be partially responsible for the
upregulation of LAT1. Low nutrient levels in tumors might elevate LAT1 levels as well, because leucine
or glutamine starvation was shown to increase LAT1 expression in vitro [93,101]. Gene amplification
might play a minor role in LAT1 overexpression since these events, to our knowledge, have not
been described so far. However, MYC amplification, that frequently occurs in cancers, is a potential
genetic alteration leading to LAT1 overexpression since c-MYC was shown to enhance LAT1 promoter
activity in vitro [102]. Also, the use of a MEK1/2 inhibitor significantly reduced Slc7a5 transcription
in mouse thyroid tumors model [59] emphasizing the role of the RAS-MEK-ERK pathway in LAT1
regulation. This underscores the fact that LAT1 elevated expression is a frequent event observed during
cancer transformation.
High LAT1 expression was associated with a significantly shorter survival in the majority of
cancers in which LAT1 was upregulated (summarized in Table 1). These studies cover the most
frequently diagnosed cancers such as breast cancer [13,72], prostate cancer [16,17], colorectal cancer [77],
and lung cancer [18–21,23,25,27–30,63,87]. Importantly, in several of these studies a positive correlation
between LAT1 levels and Ki67-positive cells was described [13,29,41,56,62], suggesting that LAT1
might support growth of highly proliferating tumors. In contrast, few studies reported no significant
association between LAT1 expression and patient survival, which was described in studies conducted
in lung cancer [22,26] and cutaneous angiosarcoma [103]. However, the study about cutaneous
angiosarcoma might be biased because the sample size (n = 52) was relatively small in order to be fully
representative [103]. Overall, LAT1 has been proposed as a promising prognostic biomarker to predict
the outcome in a variety of different cancer types, with the exception of lung cancers, in which some
discrepancies among different publications exist. Therefore, future studies are required in lung cancer
to assess whether LAT1 expression alone can serve as prognostic biomarker or whether additional
markers in combination with LAT1 need to be considered.
3. Downregulation of LAT1 and Tumor Cell Growth
In order to address whether a causal relationship between LAT1 and tumor growth exists, LAT1
expression was reduced by gene downregulation in multiple studies. LAT1 downregulation by
RNA interference was shown to impair growth of breast [14], endometrial [36], gastric [83], oral [84],
ovarian [90], pancreatic [92], and prostate [17,93,94] cancer cell lines. The studies conducted in
breast [14] and endometrial [36] cancer cell lines are particularly informative because they additionally
demonstrate an upregulation of LAT1 in patient-derived tumor tissues, further suggesting that LAT1
plays a functional role in these cancers. In line with these results, zinc finger nuclease-mediated
knockout of LAT1 in lung and colorectal cancer cell lines significantly reduced cell proliferation [78].
Moreover, LAT1 downregulation impaired migration and invasion of gastric and prostate cancer cell
lines [17,83], suggesting that the increased LAT1 expression detected in metastatic lesions compared to
the primary site [104] might play a role in the formation of metastases.
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4. Drug-Mediated Inhibition of LAT1
Based on the numerous studies demonstrating that LAT1 is overexpressed in a variety of cancers,
and the efficacy of downregulating LAT1 to obtain tumor cell growth reduction, efforts were undertaken
in order to synthesize and characterize potent inhibitors of LAT1-mediated amino-acids transport
(summarized in Table 2). Among them, BCH (2-aminobicyclo[2.2.1]heptane-2-carboxylic acid) has been
shown to reduce growth of a variety of different cancer cells including breast [14,73], prostate [93,95],
and lung [30] cancer cell lines among others (see Table 2). However, BCH is a rather unspecific
L-type amino acid transporter inhibitor that blocks LAT1–4 [9,105–107]. Thus, it remains unclear in
these studies whether the inhibition of LAT1 alone is sufficient to affect cell proliferation. In 2010,
Oda et al. published a compound (KYT-0353 or JPH203) that selectively inhibited LAT1 with an
IC50 value of 0.06 µM in HT-29 colon cancer cells that did not block LAT2 at this concentration [79].
Importantly, JPH203 inhibited HT-29 colon cancer cell proliferation with an IC50 of 4.1 µM and
significantly reduced tumor growth in vivo in a xenograft model [79]. JPH203 is a tyrosine analogue
that was designed based on the structure of the thyroid hormone triiodothyronine (T3), which is a
substrate of LAT1 and LAT2 [108,109]. JPH203 was subsequently tested in other cancer types and
successfully reduced growth of brain [71], gastric [80], head and neck [86], leukemia [50], lung [78],
kidney [78], prostate [95], thymic carcinoma [96], and thyroid cancer [59] cell lines. Importantly, LAT1
inhibition by JPH203 has demonstrated a convincing potential in vivo as shown by a diminished
tumor growth in xenograft models of human leukemia cells [50] and colon cancer cells [79]. Moreover,
we have recently shown that JPH203 induced a cytostatic growth arrest in a genetically engineered
mouse model (GEMM) of anaplastic thyroid carcinoma [59] where the immune system of the mice
remains intact. Interestingly, LAT1 expression level might not be the only factor that determines
a therapeutic response to JPH203 since we observed that LAT1 expression levels do not always
predict JPH203 sensitivity in thyroid cancer cells [59]. Similar results were independently obtained
recently in gastric cancer cells by another group [80]. Additionally, we observed in our study that the
effect of JPH203 in vitro is highly dependent on the concentration of LAT1 substrates in the culture
medium, which suggests that JPH203 acts as a competitive inhibitor of LAT1 [59]. Importantly, most
conventional culture media contain EAA concentrations that greatly exceed the physiological levels
found in plasma. Therefore, studies that address the effect of JPH203 in vitro should be performed
in customized medium that mimics more closely the clinical conditions. It is crucial to mention that
plasma levels of LAT1 substrate amino acids are significantly changed in cancer patients: plasma LAT1
substrates were found increased in lung [110,111], prostate [112], and breast cancer patients [113,114].
Furthermore, in breast cancer EAA were significantly increased in the most aggressive tumor subtype
compared to the least aggressive subtype [113]. In contrast, LAT1 substrates were found decreased in
gastrointestinal [115,116], myeloma [117], as well as pancreatic cancer patients [118]. The reason(s)
for the cancer-specific alterations of plasma EAA remains largely unknown, since the regulation of
plasma amino acid concentrations in cancer patients is highly complex. There are multiple factors
such as diet, whole-body protein metabolism, and amino acid consumption of the tumor that influence
the plasma EAA level. As an example, late-stage cancer patients are often malnourished due to
lack of appetite, which can result in decreased plasma levels of LAT1 substrates [119,120]. It is
currently poorly understood whether alterations of plasma LAT1 substrates are consistent in the tumor
microenvironment and whether plasma EAA can predict the response to LAT1 inhibition. Since JPH203
acts as a competitive inhibitor, there is a possibility that high intratumoral LAT1 substrate amino acids
may reduce or completely overcome the effect of the drug. Therefore, future studies are required in
order to address whether the intratumoral concentration of LAT1 substrates influences the efficacy
of competitive LAT1 inhibitors such as JPH203 in vivo. Additionally, to our knowledge, the effect
of plasma EAA on outcome of patients who are not malnourished has not been investigated so far.
Therefore, future studies should address the effect of plasma EAA levels on outcome of patients and
whether plasma EAA can be used as predictor for response to LAT1 inhibitors, particularly in the case
of the competitive LAT1 inhibitor JPH203.
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Table 2. Current LAT1-targeting therapies.
Class Compound Mechanism of Action In Vitro: ProliferationInhibition
Preclinical/Clinical
Studies
non-selective
LAT1 substrate BCH
Competes with the uptake of
LAT1 substrates by binding to
LAT1 and being transported into
the cells
biliary tract [61]
bladder [66]
brain [67,68]
breast [14,73]
endometrial [36]
esophageal [82]
head and neck [67,85]
lung [30]
melanoma [52,53]
ovarian [91]
prostate [93,95]
sarcoma [67]
preclinical:
biliary tract [61]
esophageal [82]
LAT1 inhibitors
compounds 28/36/42 [121] Binds to LAT1 thereby impairingtransport of LAT1 substrates
SKN103
Non-transportable blocker that
inhibits LAT1 in a
competitive manner
pancreatic/squamous cell
carcinoma [88]
JPH203
Non-transportable blocker that
inhibits LAT1 in a
competitive manner
brain [71]
colorectal [78–80]
gastric [80]
head and neck [86]
kidney [78]
leukemia [50]
lung [78]
prostate [95]
thymic carcinoma [96]
thyroid [59]
preclinical:
colorectal [79]
leukemia [50]
thyroid [59]
clinical phase 1:
[122] solid tumors
compounds 5/17
Binds covalently to the substrate
binding site of LAT1 (residue
C407) thereby impairing transport
of LAT1 substrates
cervical [76]
mAb
against LAT1 Ab1
Binds to LAT1 thereby impairing
transport of LAT1 substrates gastric, lung [81]
preclinical:
colorectal [81]
nanoparticles
SPG25 NPs ↑ accumulation inLAT1-expressing cells breast [74]
preclinical:
breast [74]
AuNU ↑ accumulation inLAT1-expressing cells breast [75]
Amphi-DOPA ↑ accumulation inLAT1-expressing cells glioblastoma [70] glioblastoma [70]
DTX-TGL ↑ accumulation inLAT1-expressing cells glioma [69]
Kongpracha et al. synthesized another LAT1-specific inhibitor (SKN103) based on the structure of
T3 and demonstrated that this compound inhibited the proliferation of pancreatic cancer cells as well
as squamous cell carcinoma cells. Furthermore, the authors showed that SKN103 in combination with
cisplatin additively reduced cell growth [88] suggesting that SKN103 could enhance the therapeutic
efficacy of chemotherapies in patients. SKN103 has not been tested in vivo so far.
Singh et al. reported recently the discovery of novel LAT1 inhibitors by using a structure-based
approach [121]. Unlike JPH203, which was rationally designed based on the structure of tyrosine, Singh
et al. used an unbiased approach by performing docking-based virtual screening of commercially
available libraries. By using this elegant method, the authors identified 13 previously unknown LAT1
ligands. Dose-response curves uncovered two novel highly potent LAT1 inhibitors with IC50 values of
0.64 µM and 1.48 µM [121]. It will be very interesting to test the anticancer properties of these promising
candidates in future studies. Moreover, the structure of these two compounds will open avenues for
the rational design of novel LAT1 inhibitors, which underscores the importance of this study.
Napolitano and colleagues aimed at finding novel LAT1 inhibitors with prolonged activity by
blocking LAT1 irreversibly. To reach this goal, they screened compounds based on dithiazole and
dithiazine scaffold, which have the potential to form disulfide bridges with C407, which is a key residue
of the substrate binding site [123]. Interestingly, out of 59 compounds they identified eight compounds
that almost completely (>90%) inhibited LAT1 transport activity at 100 µM. Furthermore, dose-response
curves revealed that the most potent inhibitors exhibited IC50 values of 0.98 µM and 0.89 µM [76]. Both
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compounds induced cell death of cervical cancer cells (SiHa) at a 10 µM concentration and this effect
was still observed after washing out the compounds [76], as expected due to the covalent binding to
LAT1 by these compounds. The breakthroughs in the discovery of highly potent covalent inhibitors of
LAT1 will enable the design of novel drugs. It will be very interesting in the future to further evaluate
all of these compounds in preclinical studies in order to test their anticancer effects, particularly in
comparison with the currently available competitive inhibitors. Covalent inhibitors of LAT1 have the
great advantage that their potency is not influenced by the availability of other LAT1 substrates, which
is not the case for competitive inhibitors. Therefore, covalent inhibitors might demonstrate a higher
efficacy in preclinical studies compared to the currently available competitive inhibitors.
Recently, Ueda et al. tested whether targeting LAT1 by monoclonal anti-LAT1 antibodies might be
a potential therapeutic approach. The authors found that the anti-LAT1 antibodies reduced proliferation
of gastric and lung cancer cells in vitro and growth of colon cancer cells in vivo [81], suggesting that
targeting LAT1 by monoclonal antibodies might be an alternative therapeutic option.
Taken together, results of the current preclinical studies assessing inhibition of LAT1 are promising
and suggest that targeting LAT1 might be a well-tolerated effective strategy in different cancer types.
5. LAT1 Binding Nanoparticles
Several studies have been published in the past recent years addressing the potential of LAT1 for
enhanced delivery of nanoparticles into cancer cells. In two independent studies, nanoparticles were
conjugated with glutamate as ligand for LAT1: Li et al. showed that glutamate-conjugated paclitaxel
nanoparticles (SPG25 NPs) exhibited increased antitumor efficiency compared to unconjugated
nanoparticles in breast cancer cells in vitro and in vivo [74]. Similarly, glutamate-conjugated
docetaxel-loaded liposomes manifested an increased cytotoxicity in vitro and higher accumulation
in the brain compared to unconjugated liposomes [69]. Other investigators have successfully used
dopamine-conjugated nanoparticles to enhance the uptake in LAT1 overexpressing cancer cells:
Ong et al. found that conjugation of L-dopa to anisotropic gold nanoparticles (AuNPs) mediated
selective photothermal ablation of breast cancer cells and sensitized cells to chemotherapy [75].
Additionally, L-dopa-conjugated liposomes demonstrated increased efficacy both in vitro as well as
in vivo compared to non-targeting liposomes in glioblastoma cells [70]. Taken together, these recent
studies suggest that LAT1-targeting nanoparticles might be a promising approach to increase the efficacy
of nanoparticle-delivered drugs. This approach might be particularly interesting for treatments that are
associated with severe side effects, since the enhanced accumulation of LAT1-targeting nanoparticles
in cancer cells might reduce accumulation in non-cancerous tissues. Further studies, particularly in
preclinical models, are warranted to confirm the increased efficacy of LAT1-targeting nanoparticles.
6. LAT1 Inhibition in Clinical Studies
The competitive LAT1 inhibitor JPH203 was recently evaluated in a first-in-human Phase 1 clinical
trial: 17 patients diagnosed with advanced solid tumors were enrolled and partial response or stable
disease was achieved in six patients. Common treatment-related adverse events included malaise,
nausea, and a grade 1 or 2 fever. Four out of the six responders were diagnosed with biliary tract cancer,
in which plasma levels of LAT1 substrates remained high [122]. Therefore, the authors concluded that
high plasma LAT1 substrate amino acids could be an important factor that determines the efficacy of
JPH203 in biliary tract cancer. However, since only 17 patients were enrolled in this phase 1 clinical
trial, these findings need to be validated in a larger cohort of patients. Importantly, based on the
promising results of the Phase 1 clinical trial, JPH203 is currently being evaluated in a Phase 2 clinical
trial in patients with advanced biliary tract cancers (UMIN Clinical Trials Registry UMIN000034080).
Future studies that identify predictive biomarkers for response to LAT1 inhibitors in patients are highly
warranted. To our knowledge, JPH203 is currently the only LAT1 inhibitor that is being evaluated in
clinical trials.
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7. Conclusions
The tumor-specific overexpression of LAT1 has been demonstrated in a variety of different cancer
types and is often associated with a worse prognosis. Due to the fact that LAT1 upregulation seems to
be a general phenomenon in cancer, targeting LAT1 might be a promising anticancer strategy. As a
result, extensive research is currently underway in order to develop potent and specific LAT1 inhibitors.
Recently, great efforts by many groups worldwide have led to the discovery of highly potent and
selective LAT1 inhibitors that exerted promising anticancer effects in preclinical as well as clinical
studies. Of particular interest are the promising results observed with JPH203 in a recent Phase 1
clinical trial, in which JPH203 was effective against biliary tract cancer. Covalent inhibitors might
exert an enhanced anticancer efficacy compared to the currently available competitive inhibitors, since
covalent inhibitors irreversibly block the transporter. Furthermore, several research groups evidenced
that LAT1-targeting nanoparticles are highly effective for LAT1-overexpressing tumors.
Taken together, currently available LAT1 inhibitors as well as LAT1-targeting nanoparticles have
shown great success in different preclinical and clinical studies.
The challenge of future studies will be to predict which patients will benefit most from LAT1
inhibitors. This is particularly important for competitive LAT1 inhibitors, since it is currently unknown
whether the levels of LAT1 substrates in the tumor microenvironment influence the efficacy of
the treatment.
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